dc.contributor.author | Fountzilas, George | en |
dc.contributor.author | Nikolaides, C. | en |
dc.contributor.author | Aravantinos, Gerasimos | en |
dc.contributor.author | Skarlos, Dimosthenis V. | en |
dc.contributor.author | Kosmidis, Paraskevas A. | en |
dc.contributor.author | Papakostas, P. | en |
dc.contributor.author | Stathopoulos, G. P. | en |
dc.contributor.author | Kontostolis, E. | en |
dc.contributor.author | Bafaloukos, Dimitrios | en |
dc.contributor.author | Pavlidis, Nicholas | en |
dc.creator | Fountzilas, George | en |
dc.creator | Nikolaides, C. | en |
dc.creator | Aravantinos, Gerasimos | en |
dc.creator | Skarlos, Dimosthenis V. | en |
dc.creator | Kosmidis, Paraskevas A. | en |
dc.creator | Papakostas, P. | en |
dc.creator | Stathopoulos, G. P. | en |
dc.creator | Kontostolis, E. | en |
dc.creator | Bafaloukos, Dimitrios | en |
dc.creator | Pavlidis, Nicholas | en |
dc.date.accessioned | 2018-06-22T09:53:05Z | |
dc.date.available | 2018-06-22T09:53:05Z | |
dc.date.issued | 1998 | |
dc.identifier.uri | https://gnosis.library.ucy.ac.cy/handle/7/41652 | |
dc.description.abstract | Forty-one patients with operable breast cancer and ≥ 10 positive axillary lymph nodes were treated with 6 cycles of dose-dense adjuvant chemotherapy consisting of epirubicin (100 mg/m2) every 2 weeks with G-CSF support. A total of 240 cycles were administered, all of them at full dose and 19 (8%) with a delay. Thirty-eight (93%) patients completed the treatment according to the protocol. The relative dose intensity of epirubicin was 0.99. Grade 3 toxicities included anemia (3%), nausea and vomiting (5%) and alopecia (71%). After a median fellow-up of 40 months, 16 (39%) patients were free of relapse. In conclusion, the present study has shown that the administration of dose-dense chemotherapy with epirubicin is feasible in the adjuvant setting with minimal toxicity. | en |
dc.language.iso | eng | en |
dc.source | Oncology | en |
dc.subject | Article | en |
dc.subject | Human | en |
dc.subject | Humans | en |
dc.subject | Adult | en |
dc.subject | Aged | en |
dc.subject | Breast neoplasms | en |
dc.subject | Female | en |
dc.subject | Middle aged | en |
dc.subject | Priority journal | en |
dc.subject | Alopecia | en |
dc.subject | Anemia | en |
dc.subject | Clinical article | en |
dc.subject | Clinical trial | en |
dc.subject | Granulocyte colony-stimulating factor | en |
dc.subject | Recombinant granulocyte colony stimulating factor | en |
dc.subject | Drug administration schedule | en |
dc.subject | Feasibility study | en |
dc.subject | Dose response | en |
dc.subject | Dose-response relationship | en |
dc.subject | Drug | en |
dc.subject | Intravenous drug administration | en |
dc.subject | Subcutaneous drug administration | en |
dc.subject | Vomiting | en |
dc.subject | Follow-up studies | en |
dc.subject | Lymphatic metastasis | en |
dc.subject | Axillary lymph node | en |
dc.subject | Breast cancer | en |
dc.subject | Cancer adjuvant therapy | en |
dc.subject | Lymph node metastasis | en |
dc.subject | Nausea | en |
dc.subject | Adjuvant chemotherapy | en |
dc.subject | Antineoplastic | en |
dc.subject | Combined modality therapy | en |
dc.subject | Feasibility studies | en |
dc.subject | Clinical protocol | en |
dc.subject | Epirubicin | en |
dc.subject | Antibiotics | en |
dc.title | Dose-dense adjuvant chemotherapy with epirubicin monotherapy in patients with operable breast cancer and ≥ 10 positive axillary lymph nodes | en |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | 10.1159/000011903 | |
dc.description.volume | 55 | |
dc.description.issue | 6 | |
dc.description.startingpage | 508 | |
dc.description.endingpage | 512 | |
dc.author.faculty | Ιατρική Σχολή / Medical School | |
dc.author.department | Ιατρική Σχολή / Medical School | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Pavlidis, Nicholas [0000-0002-2195-9961] | |
dc.contributor.orcid | Aravantinos, Gerasimos [0000-0002-2106-1713] | |
dc.gnosis.orcid | 0000-0002-2195-9961 | |
dc.gnosis.orcid | 0000-0002-2106-1713 | |